Neuraxis, INC
NRXSNYSE
$6.75
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +184.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$73.9M
Enterprise Value
$66.9M
P/E
—
P/S
17.3
P/B
12.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.3M
Net Income (TTM)
-$7.3M
Free Cash Flow (TTM)
—
Gross Margin
85.0%
Operating Margin
-169.9%
Net Margin
-170.1%
ROE
-126.7%
ROIC
—
Debt / Equity
0.0
Net Cash
$7.0M
Return 1Y
+148.2%
Company profile
We are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. We incorporated in Indiana on April 17, 2012, under the name Innovative Health Solutions, Inc. On March 11, 2022, we amended our Articles of Incorporation to change our name to Neuraxis, Inc. On June 23, 2022, we changed our state of incorporation from Indiana to Delaware. Our principal executive offices are located at 11550 N. Meridian Street, Suite 325, Carmel, IN.
- CEO
- Brian Carrico
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- Indiana
- Website
- www.neuraxis.com
Management & directors
- Carrico Brian AllenChief Executive Officer
- Carrico Thomas JoesephCRO, CCO, CPO
- Henrichs Timothy RobertChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
NRXS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.6M↑ +79.5%
Diluted EPS-$0.18↓ -45.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.7M | $2.5M | $2.7M | $3.6M |
| Gross profit | $2.4M | $2.2M | $2.3M | $3.0M |
| Operating income | -$3.4M | -$6.7M | -$7.2M | -$7.8M |
| Net income | -$4.8M | -$14.6M | -$8.2M | -$7.8M |
| Diluted EPS | -$2.77 | -$4.50 | -$1.22 | -$0.95 |
| Operating cash flow | -$2.3M | -$6.7M | -$6.1M | -$6.4M |
| Free cash flow | -$2.3M | -$6.7M | -$6.1M | -$6.5M |
| Gross margin | 88.9% | 87.7% | 86.5% | 84.2% |
| Operating margin | -125.6% | -270.9% | -266.5% | -219.4% |
| Net margin | -178.0% | -594.6% | -306.8% | -218.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $611,500.00 | $666,625.00 | $761,165.00 | $895,655.00 | $894,086.00 | $811,414.00 | $968,127.00 | $1.6M |
| Gross profit | $538,042.00 | $569,575.00 | $644,752.00 | $756,180.00 | $747,443.00 | $675,927.00 | $826,816.00 | $1.4M |
| Operating income | -$2.2M | -$1.7M | -$1.5M | -$2.3M | -$1.7M | -$2.1M | -$1.7M | -$1.7M |
| Net income | -$2.9M | -$1.8M | -$1.4M | -$2.3M | -$1.7M | -$2.1M | -$1.7M | -$1.8M |
| Diluted EPS | -$0.42 | -$0.25 | -$0.23 | -$0.33 | -$0.22 | -$0.24 | -$0.16 | -$0.18 |
| Operating cash flow | -$1.6M | -$1.4M | -$1.8M | -$1.6M | -$1.5M | -$1.4M | -$1.9M | -$1.2M |
| Free cash flow | -$1.6M | -$1.4M | -$1.8M | -$1.6M | -$1.5M | -$1.4M | -$1.9M | — |
| Gross margin | 88.0% | 85.4% | 84.7% | 84.4% | 83.6% | 83.3% | 85.4% | 86.4% |
| Operating margin | -360.9% | -247.7% | -192.7% | -256.2% | -192.1% | -258.8% | -177.3% | -108.3% |
| Net margin | -477.1% | -263.3% | -190.2% | -254.4% | -189.1% | -261.6% | -176.5% | -109.5% |
Company news
May 15, 2026
May 12, 2026
May 5, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-28 | Aharon Gil | Award | 12,304 | — | — | filing |
| 2026-04-28 | Aharon Gil | Award | 221,917 | — | — | filing |
| 2026-04-01 | Carrico Brian Allen· Chief Executive Officer | Buy | 8,060 | $1.96 | $15,797.60 | filing |
| 2026-04-01 | Henrichs Timothy Robert· Chief Financial Officer | Buy | 7,593 | $1.96 | $14,882.28 | filing |
| 2026-04-01 | Carrico Thomas Joeseph· CRO, CCO, CPO | Buy | 667 | $1.96 | $1,307.32 | filing |
| 2026-02-12 | Hannasch Brian | Buy | 40,000 | $4.92 | $196,800.00 | filing |
| 2026-02-11 | Hannasch Brian | Buy | 40,000 | $4.65 | $186,000.00 | filing |
| 2026-01-22 | Keyser Jane Elizabeth | Award | 21,598 | $4.63 | $99,998.74 | filing |
| 2026-01-22 | Watkins Bradley Mitchell | Award | 21,598 | $4.63 | $99,998.74 | filing |
| 2026-01-22 | Aharon Gil | Award | 21,598 | $4.63 | $99,998.74 | filing |
| 2026-01-22 | Ferge Kristin A | Award | 21,598 | $4.63 | $99,998.74 | filing |
| 2025-12-23 | Aharon Gil | Buy | 286,138 | $3.52 | $1.0M | filing |
| 2025-07-01 | MASIMO CORP | Sale | 531,548 | $2.25 | $1.2M | filing |
| 2025-07-01 | Hannasch Brian | Buy | 355,556 | $2.25 | $800,001.00 | filing |
| 2025-07-01 | MASIMO CORP | Sale | 289,779 | $2.25 | $652,002.75 | filing |
| 2025-07-01 | MASIMO CORP | C | 289,779 | $0.00 | $28.98 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.